GO:0006476 protein deacetylation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006476 (protein deacetylation) is the biological process that removes an acetyl group (CH3CO-) from a protein amino acid, reversing the effects of acetylation and controlling protein activity, localization, and stability.
• Sirtuin deacetylases (SIRT1-SIRT7) are NAD+-dependent enzymes that couple protein deacetylation to cellular energy status and metabolic regulation.
• Protein deacetylation regulates inflammation, autophagy, inflammasome activation, fatty acid oxidation, and mitochondrial metabolism through deacetylation of specific substrates such as Beclin1, NLRC4, and ACSL5.
• Dysregulated protein deacetylation contributes to cancer immune escape, acute kidney injury, nonalcoholic fatty liver disease, and ageing-related phenotypes.
• SIRT2 can be delivered from oligodendrocytes to axons to deacetylate mitochondrial proteins and enhance axonal energy metabolism, showing that deacetylation can act across cell boundaries.
• Studying protein deacetylation requires integrated approaches including CRISPR knockout/knock-in models, acetylome proteomics, and functional assays for substrate-specific deacetylation.
Description
Protein deacetylation (GO:0006476) is the enzymatic removal of an acetyl group from a protein amino acid, a post-translational modification that reverses protein acetylation and dynamically controls protein function. This process is central to cellular signaling because acetylation and deacetylation cycles regulate enzyme activity, protein-protein interactions, DNA binding, and protein stability. The acetyl group removed is CH3CO-, derived from acetic acid, and its removal is catalyzed by deacetylases including the sirtuin family and histone deacetylases. Researchers study protein deacetylation because it links metabolic state to gene regulation, inflammation, autophagy, and cell survival. SIRT1, for example, uses NAD+ as a cofactor and functions as a metabolic sensor whose deacetylase activity is modulated by cellular energy levels. Beyond metabolism, protein deacetylation controls innate immune signaling through NLRC4 deacetylation by SIRT3, which promotes inflammasome activation. In the nervous system, SIRT2-mediated deacetylation of mitochondrial proteins supports axonal energy metabolism, illustrating the broad physiological reach of this process. Because deacetylation influences disease pathways ranging from tumor immune escape to fatty liver disease, it is a high-priority target for mechanistic and therapeutic research.
protein deacetylation At A Glance
| GO ID | GO:0006476 |
|---|---|
| GO term | protein deacetylation |
| Ontology | biological_process |
| Synonym | protein amino acid deacetylation |
| Definition | The removal of an acetyl group from a protein amino acid; an acetyl group is CH3CO-, derived from acetic (ethanoic) acid. |
| Major function | Reverses protein acetylation to control protein activity, interactions, localization, and stability. |
| Key enzyme families | Sirtuins (SIRT1-SIRT7) and other deacetylases. |
| Cofactor | Sirtuin-mediated deacetylation depends on NAD+. |
| Representative substrates | Beclin1, NLRC4, ACSL5, mitochondrial proteins, PD-L1 pathway components. |
What Is GO:0006476?
Protein deacetylation (GO:0006476) is defined as the removal of an acetyl group from a protein amino acid, where the acetyl group is CH3CO-, derived from acetic (ethanoic) acid. In practical terms, it is the enzymatic reversal of protein acetylation, catalyzed by deacetylases such as sirtuins, and it changes the chemical and functional properties of the target protein.
Why Is protein deacetylation Important in Cell Biology?
Protein deacetylation is important because it provides a reversible, energy-sensitive switch that adjusts protein function in response to cellular conditions, and its dysregulation is linked to major human diseases including cancer, inflammatory conditions, metabolic liver disease, acute kidney injury, and ageing.
• Controls metabolic regulation by reversing acetylation on metabolic enzymes and regulators.
• Regulates inflammation through SIRT1 and SIRT3-dependent deacetylation of immune signaling proteins.
• Promotes autophagy via Beclin1 deacetylation, protecting against sepsis-induced acute kidney injury.
• Supports hepatic fatty acid oxidation through cytoplasmic SIRT6-mediated ACSL5 deacetylation, impeding nonalcoholic fatty liver disease.
• Enables tumor immune escape via SIRT2-mediated deacetylation that stabilizes PD-L1.
• Enhances axonal energy metabolism through transcellular delivery of SIRT2 to deacetylate mitochondrial proteins.
• Is modulated by natural compounds such as lithocholic acid, which activates sirtuins and AMPK to slow ageing.
• Provides a druggable node for cancer immunotherapy, metabolic disease, and neuroprotection.
• Serves as a key post-translational modification for integrating NAD+ availability with cellular stress responses.
What Happens During protein deacetylation?
Recognition of acetylated substrate
In simple terms: The deacetylase enzyme finds and binds a target protein that carries an acetyl tag.
Protein deacetylation begins when a deacetylase recognizes an acetylated lysine residue on a substrate protein. Sirtuins such as SIRT1, SIRT2, SIRT3, and SIRT6 bind specific substrates, including Beclin1, mitochondrial proteins, NLRC4, and ACSL5, and this substrate selectivity determines which cellular pathways are affected. The interaction is often regulated by cellular context, such as energy status or subcellular localization.
NAD+-dependent catalysis
In simple terms: The enzyme uses NAD+ as a helper molecule to chemically remove the acetyl group.
Sirtuin-mediated deacetylation is NAD+-dependent, coupling the removal of the acetyl group to the cellular energy state. This reaction converts NAD+ to nicotinamide and O-acetyl-ADP-ribose while restoring the lysine residue to its unacetylated form. Because NAD+ levels fluctuate with metabolism, this catalytic step makes protein deacetylation a metabolic sensor.
Substrate-specific functional consequences
In simple terms: Once the acetyl tag is removed, the target protein changes its behavior.
Deacetylation alters substrate activity, stability, or interactions. SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation, while SIRT1-mediated Beclin1 deacetylation activates autophagy and attenuates sepsis-induced acute kidney injury. Cytoplasmic SIRT6 deacetylates ACSL5 to facilitate hepatic fatty acid oxidation and impede nonalcoholic fatty liver disease. SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 stabilization and tumor immune escape.
Cross-compartment and transcellular deacetylation
In simple terms: Deacetylation can happen in different parts of the cell and even be delivered from one cell to another.
Protein deacetylation occurs in multiple compartments, including the nucleus, cytoplasm, and mitochondria. Oligodendrocytes enhance axonal energy metabolism by transcellular delivery of SIRT2, which deacetylates mitochondrial proteins in axons. This demonstrates that deacetylation can be spatially regulated and can coordinate metabolism across cell types.
Integration with ageing and metabolic signaling
In simple terms: Deacetylation is tied to how cells respond to diet, energy, and ageing signals.
Protein deacetylation is integrated with ageing and metabolic pathways. Lithocholic acid binds TULP3 to activate sirtuins and AMPK, slowing down ageing in model systems. SIRT1 and its regulation are linked to inflammatory responses, showing that deacetylation connects metabolism, inflammation, and ageing.
Key Genes Involved in GO:0006476 protein deacetylation
The following genes and proteins are central to protein deacetylation (GO:0006476) based on published mechanistic studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SIRT1 | NAD+-dependent deacetylase; deacetylates Beclin1 and regulates inflammation and metabolism | Autophagy, acute kidney injury, inflammation, metabolic regulation |
| SIRT2 | Deacetylates mitochondrial proteins; delivered transcellularly to axons; deacetylates USP22 pathway components | Axonal energy metabolism, tumor immune escape |
| SIRT3 | Mitochondrial deacetylase; deacetylates NLRC4 | Inflammasome activation and innate immunity |
| SIRT6 | Cytoplasmic deacetylase; deacetylates ACSL5 | Nonalcoholic fatty liver disease and fatty acid oxidation |
| USP22 | Deubiquitinase whose catalytic function is activated by SIRT2-mediated deacetylation | PD-L1 stabilization and tumor immune escape |
| NLRC4 | Inflammasome sensor deacetylated by SIRT3 | Inflammasome activation |
| ACSL5 | Long-chain acyl-CoA synthetase deacetylated by SIRT6 | Hepatic fatty acid oxidation and NAFLD |
| Beclin1 | Autophagy regulator deacetylated by SIRT1 | Sepsis-induced acute kidney injury and autophagy |
| TULP3 | Target of lithocholic acid that activates sirtuins and AMPK | Ageing and metabolic regulation |
| AMPK | Energy sensor activated downstream of TULP3/lithocholic acid signaling | Ageing and metabolic homeostasis |
| PD-L1 | Immune checkpoint protein stabilized via SIRT2-USP22 axis | Tumor immune escape and immunotherapy |
| NAD+ | Essential cofactor for sirtuin-mediated deacetylation | Metabolic sensing and deacetylase activity |
| Mitochondrial proteins | Substrates deacetylated by SIRT2 in axons | Axonal energy metabolism |
| Histone deacetylases (HDACs) | Deacetylases that remove acetyl groups from histone and non-histone proteins | General protein deacetylation and gene regulation |
How Is protein deacetylation Regulated?
Protein deacetylation is regulated by cellular energy status through NAD+ availability, which directly controls sirtuin activity. SIRT1 expression and activity are modulated in inflammatory contexts, linking deacetylation to immune signaling. Lithocholic acid binds TULP3 to activate sirtuins and AMPK, providing a dietary/metabolic input into deacetylation pathways. Subcellular localization further regulates deacetylation; for example, cytoplasmic SIRT6 deacetylates ACSL5, while SIRT2 delivered to axons deacetylates mitochondrial proteins. These layers of regulation allow protein deacetylation to respond to metabolic, inflammatory, and ageing-related cues.
protein deacetylation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT2/USP22 | Tumor immune escape via PD-L1 stabilization | Cancer cell lines with SIRT2 knockout or USP22 deacetylation-site mutation |
| SIRT6/ACSL5 | Nonalcoholic fatty liver disease | Hepatocyte models with SIRT6 knockout or ACSL5 acetylation-site knock-in |
| SIRT1/Beclin1 | Sepsis-induced acute kidney injury | Renal tubular cells with SIRT1 knockout or Beclin1 deacetylation-mimetic knock-in |
| SIRT3/NLRC4 | Inflammasome activation | Macrophages with SIRT3 knockout or NLRC4 acetylation-site mutation |
| SIRT2/mitochondrial proteins | Axonal energy metabolism and neurodegeneration | Oligodendrocyte-neuron co-culture with SIRT2 knockout or tagged SIRT2 knock-in |
Cancer and tumor immune escape
SIRT2-mediated deacetylation activates USP22 catalytic function, leading to PD-L1 protein stabilization and tumor immune escape. This links protein deacetylation directly to immune checkpoint regulation and suggests that deacetylase activity can shape immunotherapy responses.
Metabolic and liver disease
Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation. This positions protein deacetylation as a protective mechanism in lipid metabolism and a potential target for NAFLD research.
Acute kidney injury and inflammation
SIRT1 attenuates sepsis-induced acute kidney injury via Beclin1 deacetylation-mediated autophagy activation. SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation, connecting deacetylation to innate immune responses. SIRT1 regulation is also broadly linked to inflammation.
Ageing and neurodegeneration
Lithocholic acid binds TULP3 to activate sirtuins and AMPK to slow down ageing, implicating deacetylation in longevity pathways. Oligodendrocytes enhance axonal energy metabolism by deacetylation of mitochondrial proteins through transcellular delivery of SIRT2, highlighting a role in neuronal support and potentially in neurodegenerative contexts.
From protein deacetylation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a deacetylase alter substrate acetylation and function? | CRISPR knockout of SIRT1, SIRT2, SIRT3, or SIRT6 in relevant cell lines |
| Does a specific acetylation site control protein function? | Point mutation of the acetylated lysine to arginine (deacetylation mimic) or glutamine (acetylation mimic) |
| Does a disease-associated deacetylation event require a specific substrate interaction? | Knock-in of tagged substrate (e.g., Flag-ACSL5) for interaction and acetylation assays |
| Can deacetylation be tracked in live cells? | Knock-in of fluorescent or proximity-labeling tags on deacetylases or substrates |
| Does overexpression of a deacetylase rescue a phenotype? | Overexpression of SIRT1, SIRT2, SIRT3, or SIRT6 in disease-relevant cells |
| Does a compound modulate deacetylation? | Reporter cells with deacetylation-dependent readouts and CRISPR-engineered substrate mutants |
How to Study the protein deacetylation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Acetylome mass spectrometry | Global acetylation levels on lysine residues | Identify deacetylation substrates after SIRT knockout or overexpression |
| Co-immunoprecipitation | Physical interaction between deacetylase and substrate | Validate SIRT2-USP22 or SIRT6-ACSL5 complexes |
| Western blot with pan-acetyl-lysine antibodies | Changes in total or substrate-specific acetylation | Confirm deacetylation of Beclin1, NLRC4, or ACSL5 |
| Autophagy flux assay | Autophagic degradation activity | Test Beclin1 deacetylation effects on autophagy |
| Inflammasome activation assay | Caspase-1 activation and IL-1beta release | Assess NLRC4 deacetylation by SIRT3 |
| Seahorse metabolic assay | Oxygen consumption and fatty acid oxidation | Measure ACSL5 deacetylation effects on hepatic metabolism |
| Live-cell imaging | Subcellular localization and transcellular delivery | Track SIRT2 delivery to axons and mitochondrial protein deacetylation |
| Reporter assays | Transcriptional or signaling output | Screen compounds that modulate sirtuin activity |
Acetylome proteomics
Acetylome profiling using mass spectrometry identifies acetylated lysine residues and quantifies changes upon deacetylase perturbation. This approach can reveal substrate-specific deacetylation events such as ACSL5 deacetylation by SIRT6 or NLRC4 deacetylation by SIRT3.
Co-immunoprecipitation and interaction assays
Co-immunoprecipitation and proximity assays detect physical interactions between deacetylases and substrates, such as SIRT2-USP22 or SIRT6-ACSL5, confirming substrate specificity and complex formation.
Functional autophagy and inflammasome assays
Autophagy flux assays and inflammasome activation readouts measure the downstream consequences of deacetylation, as shown for Beclin1 deacetylation in autophagy and NLRC4 deacetylation in inflammasome activation.
Metabolic and imaging assays
Seahorse metabolic analysis, fatty acid oxidation measurements, and live-cell imaging of tagged proteins assess how deacetylation affects metabolism and localization, including transcellular SIRT2 delivery to axons.
How CRISPR Can Be Used to Study GO:0006476 protein deacetylation
Knockout
CRISPR knockout of deacetylase genes such as SIRT1, SIRT2, SIRT3, or SIRT6 eliminates enzyme activity and reveals substrate acetylation changes and downstream phenotypes, including autophagy defects, inflammasome dysregulation, and altered fatty acid oxidation.
Point Mutation
Point mutation of the acetylated lysine on a substrate to arginine (deacetylation mimic) or glutamine (acetylation mimic) tests whether a specific deacetylation event is required for function, as applied to PD-L1 pathway components and ACSL5.
Knock-in
Knock-in of epitope or fluorescent tags on deacetylases or substrates enables tracking of protein localization, interaction, and deacetylation dynamics, including SIRT2 delivery to axons and ACSL5 acetylation-site studies.
Overexpression
Overexpression of SIRT1, SIRT2, SIRT3, or SIRT6 can rescue or exacerbate phenotypes, providing gain-of-function evidence for deacetylation in acute kidney injury, tumor immune escape, and metabolic disease.
How EDITGENE Supports protein deacetylation Research
Researchers studying protein deacetylation-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, which requires precise genetic models that isolate deacetylase activity, substrate acetylation sites, and downstream signaling.
Contact EDITGENE today to design your custom CRISPR model for protein deacetylation research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| SIRT6 Knockout HEK293 Cell Line | EDJ-KQ948 | Human | 51548 | Details Get a Quote |
| SIRT1 Knockout HEK293 Cell Line | EDJ-KQ1128 | Human | 23411 | Details Get a Quote |
| SIRT2 Knockout HEK293 Cell Line | EDJ-KQ1129 | Human | 22933 | Details Get a Quote |
| HDAC6 Knockout HEK293 Cell Line | EDJ-KQ2396 | Human | 10013 | Details Get a Quote |
| SIRT5 Knockout HEK293 Cell Line | EDC07605 | Human | 23408 | Details Get a Quote |
| HDAC7 Knockout HEK293 Cell Line | EDJ-KQ3535 | Human | 51564 | Details Get a Quote |
| SIRT3 Knockout HEK293 Cell Line | EDC90414 | Human | 23410 | Details Get a Quote |
| SIRT7 Knockout HEK293 Cell Line | EDJ-KQ15266 | Human | 51547 | Details Get a Quote |
| SIRT2 Knockout A-549 Cell Line | EDJ-KQ18084 | Human | 22933 | Details Get a Quote |
| SIRT7 Knockout A-549 Cell Line | EDJ-KQ18097 | Human | 51547 | Details Get a Quote |
| SIRT6 Knockout A-549 Cell Line | EDJ-KQ19936 | Human | 51548 | Details Get a Quote |
| SIRT6 Knockout HeLa Cell Line | EDJ-KQ19937 | Human | 51548 | Details Get a Quote |
| SIRT3 Knockout A-549 Cell Line | EDJ-KQ45951 | Human | 23410 | Details Get a Quote |
| SIRT3 Knockout HCT 116 Cell Line | EDJ-KQ45952 | Human | 23410 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About protein deacetylation
What is protein deacetylation GO:0006476?
Protein deacetylation (GO:0006476) is the biological process that removes an acetyl group (CH3CO-) from a protein amino acid, reversing acetylation and regulating protein function.
What genes are involved in protein deacetylation?
Key genes include SIRT1, SIRT2, SIRT3, SIRT6, and other deacetylases, along with substrates such as Beclin1, NLRC4, ACSL5, and USP22.
How does SIRT1 mediate protein deacetylation?
SIRT1 is an NAD+-dependent deacetylase that removes acetyl groups from substrates such as Beclin1, regulating autophagy and inflammation.
What is the role of protein deacetylation in cancer?
SIRT2-mediated deacetylation activates USP22 to stabilize PD-L1, promoting tumor immune escape.
How is protein deacetylation linked to metabolism?
Sirtuin deacetylation depends on NAD+ and regulates metabolic pathways, including hepatic fatty acid oxidation via SIRT6-mediated ACSL5 deacetylation.
Can protein deacetylation be studied with CRISPR?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to dissect deacetylase function and substrate-specific deacetylation.
What diseases are associated with protein deacetylation?
Protein deacetylation is linked to cancer immune escape, nonalcoholic fatty liver disease, sepsis-induced acute kidney injury, inflammasome-related inflammation, and ageing.
What is the role of SIRT3 in inflammasome activation?
SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation.
How does SIRT2 affect axonal energy metabolism?
Oligodendrocytes deliver SIRT2 to axons, where it deacetylates mitochondrial proteins to enhance axonal energy metabolism.
What methods are used to measure protein deacetylation?
Acetylome mass spectrometry, co-immunoprecipitation, western blotting with acetyl-lysine antibodies, and functional assays are commonly used.
Conclusion
Protein deacetylation (GO:0006476) is a fundamental post-translational process that removes acetyl groups from proteins and controls metabolism, inflammation, autophagy, and immune responses. Its dysregulation contributes to cancer, metabolic liver disease, acute kidney injury, and ageing-related phenotypes. Continued research using CRISPR models and acetylome profiling will clarify how specific deacetylation events can be targeted therapeutically.
References
- 1. Li N et al.. 2026. SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape.. J Clin Invest 136(14) PMID: 42228402
- 2. Yang Y et al.. 2022. Regulation of SIRT1 and Its Roles in Inflammation.. Front Immunol 13:831168 PMID: 35359990
- 3. Guan C et al.. 2021. SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation.. Theranostics 11(8):3981-3995 PMID: 33664876
- 4. Yu J et al.. 2010. Protein deacetylation by SIRT1: an emerging key post-translational modification in metabolic regulation.. Pharmacol Res 62(1):35-41 PMID: 20026274
- 5. Qu Q et al.. 2025. Lithocholic acid binds TULP3 to activate sirtuins and AMPK to slow down ageing.. Nature 643(8070):201-209 PMID: 39695235
- 6. Hou T et al.. 2022. Cytoplasmic SIRT6-mediated ACSL5 deacetylation impedes nonalcoholic fatty liver disease by facilitating hepatic fatty acid oxidation.. Mol Cell 82(21):4099-4115.e9 PMID: 36208627
- 7. Chamberlain KA et al.. 2021. Oligodendrocytes enhance axonal energy metabolism by deacetylation of mitochondrial proteins through transcellular delivery of SIRT2.. Neuron 109(21):3456-3472.e8 PMID: 34506725
- 8. Deng Z et al.. 2021. SIRT1 attenuates sepsis-induced acute kidney injury via Beclin1 deacetylation-mediated autophagy activation.. Cell Death Dis 12(2):217 PMID: 33637691
